Literature DB >> 34002220

Site- and Taxa-Specific Disease-Associated Oral Microbial Structures Distinguish Inflammatory Bowel Diseases.

Hari K Somineni1,2, Jordan H Weitzner1, Suresh Venkateswaran1, Anne Dodd1, Jarod Prince1, Arjuna Karikaran1, Cary G Sauer1, Shelly Abramowicz3, Michael E Zwick4, David J Cutler4, David T Okou1, Pankaj Chopra4, Subra Kugathasan1,2,4.   

Abstract

BACKGROUND: The gut and oral microbiome have independently been shown to be associated with inflammatory bowel disease (IBD). However, it is not known to what extent gut and oral microbial disease markers converge in terms of their composition in IBD. Further, the spatial and temporal variation within the oral microenvironments of IBD remain to be elucidated. PATIENTS AND METHODS: We used a prospectively recruited cohort of patients with IBD (n = 47) and unrelated healthy control patients (n = 18) to examine the spatial and temporal distribution of microbiota within the various oral microenvironments, represented by saliva, tongue, buccal mucosa, and plaque, and compared them with stool. Microbiome characterization was performed using 16S rRNA gene sequencing.
RESULTS: The oral microbiome displayed IBD-associated dysbiosis, in a site- and taxa-specific manner. Plaque samples depicted a relatively severe degree of dysbiosis, and the disease-associated dysbiotic bacterial groups were predominantly the members of the phylum Firmicutes. Our 16S rRNA gene analyses show that oral microbiota can distinguish patients with IBD from healthy control patients, with salivary microbiota performing the best, closely matched by stool and other oral sites. Longitudinal profiles of microbial composition suggest that some taxa are more consistently perturbed than others, preferentially in a site-dependent fashion.
CONCLUSIONS: Collectively, these data indicate the potential of using oral microbial profiles in screening and monitoring patients with IBD. Furthermore, these results support the importance of spatial and longitudinal microbiome sampling to interpret disease-associated dysbiotic states and eventually to gain insights into disease pathogenesis.
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  16S rRNA; IBD; longitudinal; microbiome; microbiota; spatial; temporal

Mesh:

Substances:

Year:  2021        PMID: 34002220      PMCID: PMC8599042          DOI: 10.1093/ibd/izab082

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  46 in total

1.  Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original?

Authors:  Melissa A Shepanski; Jonathan E Markowitz; Petar Mamula; Linda B Hurd; Robert N Baldassano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-07       Impact factor: 2.839

2.  Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

Authors:  Lisa J Herrinton; Liyan Liu; James D Lewis; Patricia M Griffin; James Allison
Journal:  Am J Gastroenterol       Date:  2008-08       Impact factor: 10.864

3.  Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.

Authors:  Patrick D Schloss; Sarah L Westcott; Thomas Ryabin; Justine R Hall; Martin Hartmann; Emily B Hollister; Ryan A Lesniewski; Brian B Oakley; Donovan H Parks; Courtney J Robinson; Jason W Sahl; Blaz Stres; Gerhard G Thallinger; David J Van Horn; Carolyn F Weber
Journal:  Appl Environ Microbiol       Date:  2009-10-02       Impact factor: 4.792

4.  Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.

Authors:  Richard Hansen; Richard K Russell; Caroline Reiff; Petra Louis; Freda McIntosh; Susan H Berry; Indrani Mukhopadhya; W Michael Bisset; Andy R Barclay; Jon Bishop; Diana M Flynn; Paraic McGrogan; Sabarinathan Loganathan; Gamal Mahdi; Harry J Flint; Emad M El-Omar; Georgina L Hold
Journal:  Am J Gastroenterol       Date:  2012-10-09       Impact factor: 10.864

5.  VSEARCH: a versatile open source tool for metagenomics.

Authors:  Torbjørn Rognes; Tomáš Flouri; Ben Nichols; Christopher Quince; Frédéric Mahé
Journal:  PeerJ       Date:  2016-10-18       Impact factor: 2.984

6.  A framework for human microbiome research.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

7.  Differential abundance analysis for microbial marker-gene surveys.

Authors:  Joseph N Paulson; O Colin Stine; Héctor Corrada Bravo; Mihai Pop
Journal:  Nat Methods       Date:  2013-09-29       Impact factor: 28.547

8.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Authors:  Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan
Journal:  Genome Med       Date:  2016-07-13       Impact factor: 11.117

Review 9.  The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?

Authors:  Khalid Elmaghrawy; Séamus Hussey; Gary P Moran
Journal:  Front Pediatr       Date:  2021-01-21       Impact factor: 3.418

10.  Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing.

Authors:  Sandeep A Walujkar; Dhiraj P Dhotre; Nachiket P Marathe; Parimal S Lawate; Renu S Bharadwaj; Yogesh S Shouche
Journal:  Gut Pathog       Date:  2014-06-14       Impact factor: 4.181

View more
  1 in total

1.  Impact of sleep on the microbiome of oral biofilms.

Authors:  Maki Sotozono; Nanako Kuriki; Yoko Asahi; Yuichiro Noiri; Mikako Hayashi; Daisuke Motooka; Shota Nakamura; Mikiyo Yamaguchi; Tetsuya Iida; Shigeyuki Ebisu
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.